Treatment and outcomes for early-stage non-small cell lung cancer in China
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
AstraZeneca · NCT07316062
This chart review will look at treatment choices, biomarker testing, and outcomes for adults diagnosed with stage I–III non-small cell lung cancer in China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AstraZeneca (industry) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT07316062 on ClinicalTrials.gov |
What this trial studies
This multi-center chart review will extract medical record data from participating hospitals in China to describe initial treatment patterns, biomarker testing, and clinical outcomes for adults with stage I–III NSCLC. Patients diagnosed in specified windows (May–Dec 2025, May–Dec 2026, or May–Dec 2027) who meet inclusion criteria will be included and relevant data such as staging, treatments, biomarker results, and follow-up will be collected. Analyses will compare patterns over time and across centers to characterize changes in standard-of-care and use of selected regimens. No interventional therapies are given as part of this observational review.
Who should consider this trial
Good fit: Adults (≥18 years) in China with a primary diagnosis of stage I–III NSCLC during the specified diagnosis windows who were not enrolled in interventional clinical trials at initial diagnosis are ideal candidates.
Not a fit: Patients with metastatic (stage IV) disease, non-primary NSCLC, concurrent or recent other tumors, pregnancy at diagnosis, or participation in interventional trials at diagnosis are excluded and are unlikely to benefit from this review.
Why it matters
Potential benefit: If successful, the findings could reveal common treatment pathways and testing gaps to help clinicians improve care for future patients with early-stage NSCLC in China.
How similar studies have performed: Similar retrospective chart reviews have been widely used to document real-world treatment and testing patterns and have informed guidelines and health-care planning, though they do not test new therapies directly.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stage I-III at initial NSCLC diagnosis * Aged ≥18 years at first diagnosis of NSCLC * Timeframe of NSCLC diagnosis: For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027 Exclusion Criteria: * NSCLC is not the primary cancer diagnosis * Patients with a recent history of other tumor or concurrent other tumor * Patients participating in interventional clinical trials at time of initial diagnosis * Patients with positive pregnancy status at the time of diagnosis
Where this trial is running
Beijing
- Research Site — Beijing, China (RECRUITING)
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-Small-Cell Lung, NSCLC, chart review